ClinicalTrials.gg
RecruitingNCT07046364Updated Jul 1, 2025

Remimazolam and Emergence Delirium in Pediatrics

A Phase 4 interventional study of Remimazolam and Normal Saline in Pediatric, Neurosurgery and Sevoflurane Anesthesia, sponsored by Peking University First Hospital. Recruiting at 2 sites in China. Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Peking University First Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2025, registered Jun 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
1 Year to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing remimazolam in Emergence Delirium — 9 open to participants now, 9 under way, none of them phase 3. remimazolam · Emergence Delirium.

Planned enrollment
4th of 13
248 · median 138
Started
2025
with 1 other
Phase 4
5 of 13
5 open now
Registered
6th of 13
by date
Lead sponsor
2 of 13
Peking University First Hospital

Among the 13 studies testing remimazolam in Emergence Delirium, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 6th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

9 of the 13 studies testing remimazolam in Emergence Delirium are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About remimazolam

remimazolam: first FDA approval 2020 (BYFAVO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 1 Year to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing remimazolam in Emergence Delirium, or all of them as a file.
02

Study summary

Emergence delirium is a common complication in pediatrics undergoing neurosurgery. Previous study showed that a single bolus of remimazolam was associated with lower incidence of postoperative agitation. Present study was designed to investigate if remimazolam supplemented to sevoflurane anesthesia could decrease the risk of emergence delirium in pediatrics undergoing neurosurgery.

03

Conditions studied

  • Pediatric
  • Neurosurgery
  • Sevoflurane Anesthesia
  • Remimazolam
  • Emergence Delirium

Browse trials for

Keywords

  • emergence delirium
  • remimazolam
  • pediatric
  • neurosurgery
  • sevoflurane anesthesia
04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 1 to 6 years old
  • Planned to receive elective neurosurgery under general anesthesia
  • Expected duration of surgery > 1 hour

Exclusion criteria

Exclusion Criteria:

  • Allergy to benzodiazepine
  • Use of other sedatives within 12 hours before surgery such as benzodiazepines, propofol, chloral hydrate, etc.,
  • IV or above
  • Unable to complete emergence delirium assessment, such as language, hearing or vision impairment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Remimazolam group

    A loading dose of remimazolam 0.3 mg/Kg was given at anesthesia induction and followed with 1 mg/Kg/h until 10 minutes before the end of surgery. Sevoflurane was used to maintain BIS between 40-60.

    Drug: Remimazolam

  • Placebo comparator
    Normal saline group

    An identical volume of normal saline was given as placebo. Patients received sevoflurane to maintain anesthesia depth (BIS) 40-60

    Drug: Normal Saline

Interventions

  • After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of remimazolam), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of remimazolam). The infusion is expected to stop 10 minutes before the end of the surgery.

  • DrugNormal Saline

    After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of normal saline), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of normal saline). The infusion is expected to stop 10 minutes before the end of the surgery.

06

What researchers measure

Primary outcomes

  1. Emergence delirium

    The Cornell Assessment of Pediatric Delirium (CAPD) was used to assess delirium. It consists of a total of 8 items, with each item scored from 0 to 4. Delirium can be diagnosed when the total score is ≥ 10.

    Time frame: The subjects were evaluated at 10 minutes, 20 minutes, 30 minutes after admission to PACU or before discharge

Secondary outcomes

  1. Postoperative delirium

    The Cornell Assessment of Pediatric Delirium (CAPD) scale was used to assess whether the subjects developed delirium. It consists of a total of 8 items, with each item scored from 0 to 4. Delirium can be diagnosed when the total score is ≥ 10.

    Time frame: Delirium was assessed at 07:00~09:00 and 17:00~20:00 on the 1st, 2nd and 3rd day after surgery

  2. Pain score

    The FLACC behavioral rating scale was used to evaluate the pain intensity. It mainly includes five indicators: Facial Expression, Legs, Activity, Cry, and Consolability. The score is the sum of the above five indicators, ranging from a minimum of 0 to a maximum of 10. A higher score indicates more obvious discomfort and pain.

    Time frame: Pain intensity was assessed at 07:00~09:00 and 17:00~20:00 on the 1st, 2nd and 3rd day after surgery

  3. Sleep quality within 3 days after surgery

    The Numeric Rating Scale (NRS) was used for sleep quality assessment of children by their parents/caregivers within 3 days after surgery. The scores of NRS ranging from a minimum of 0 to a maximum of 10. A lower score indicates poorer sleep quality.

    Time frame: Within 3 days after surgery

  4. Sleep quality 7 days after surgery and 1 month after surgery

    The Tayside Children's Sleep Questionnaire (TCSQ) was adopted to assess the sleep quality 7 days after surgery and 1 month after surgery.The TCSQ consists of 10 questions, with scores ranging from a minimum of 0 to a maximum of 40. A higher score indicates poorer sleep quality.

    Time frame: 7 days after surgery and 1 month after surgery

  5. Postoperative adverse behavior change

    Post-hospitalization behavior questionnaire (PHBQ) was used to evaluate the postoperative adverse behavior change. It consists of 26 items, with scores ranging from a minimum of -52 to a maximum of 52. A higher score indicates poorer sleep quality.

    Time frame: 1st, 3rd days after surgery

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 24 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2025
First posted
Jul 1, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046364
Responsible party
Mu Dong Liang (Professor, Peking University First Hospital) — Principal investigator
First posted
Jul 1, 2025
Start date
Jan 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jul 1, 2025

Study contacts

Dong-liang Mu
Contact
mudongliang@bjmu.edu.cn
+86 010 83575138

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam

Start the discussion